Tooba Murshedkar

TL;DR: PfSPZ-CVac is a highly efficacious vaccine candidate that could be used for combination mass drug administration and a mass vaccination program approach to eliminate malaria from geographically defined areas when able to optimize the immunization regimen.

TL;DR: It is suggested that PfSPZ Vaccine conferred durable protection to malaria through long-lived tissue-resident T cells and that administration of higher doses may further enhance protection.

TL;DR: PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria season and was well tolerated and safe.

TL;DR: Evidence is provided that this Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine) induces antigen-specific IFN-γ-producing CD8 and CD4 T cells that recognize both the homologous and the heterologous Pf strain.

TL;DR: It is demonstrated for the first time to the authors' knowledge that PfSPZ Vaccine can protect against a 3-week heterologous CHMI in a limited group of malaria-naive adult subjects and provides a foundation for developing an optimized immunization regimen for preventing malaria.